Interim report January-March 2003

Tripep AB (publ) - Interim report, January - March 2003 · Planned cost reductions have been implemented, resulting in a more than 50 per cent cut, without effecting R&D * Loss for the period -4.8 (-11.2) * R&D costs for the period 2.7 (2.8) · Research focusing on MetaboliteX, GPG®'s antiviral metabolite, is continuing. · Discussions are under way with several partners concerning the consolidation of operations through acquisitions. · The AGM adopted a buy-back programme whereby shareholders are being offered the chance to sell one share in ten for SEK 30. · The AGM also decided to issue a maximum of 750,000 debt instruments with detachable warrants. For more information, please contact Johan Ihre, President and CEO Tel.: +46 8 449 84 80, mobile phone: +46 707 33 44 25 E-mail: johan.ihre@tripep.se or Anders Vahlne, VP, Head of Research Tel.: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@labmed.ki.se Web site: www.tripep.se Tripep is a biotechnology research company that develops and commercialises candidate drugs based on patented technologies. Its main focuses are: - research and development of a potential HIV-inhibiting drug, - preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and Hepatitis C, and - the RAS ® technology platform. For more details of the company's technologies, please refer to the company's web site at www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/04/30/20030430BIT00180/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/04/30/20030430BIT00180/wkr0002.pdf The full report